A pooled analysis of two prior trials suggests patients with a variety of cardiac index scores saw improvement when Winrevair ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Pulmonary angiography, specifically the computed tomographic version, is the gold standard for diagnosing lung embolism.

Cibotercept is a fusion protein commercialized by Keros Therapeutics, with a leading Phase II program in Pulmonary Arterial Hypertension.

NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros ...

Keros Therapeutics, Inc.'s stock plummets 75% due to safety concerns in Phase 2 trial, but partnership with Takeda may offer stability. Click for more on KROS.

AZD-3427 is commercialized by AstraZeneca, with a leading Phase II program in Congestive Heart Failure (Heart Failure).

NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros ...

A new study published in the Frontiers in Cardiovascular Medicine journal showed that right ventricular (RV) dysfunction is ...

I was diagnosed with COPD last year after struggling with multiple symptoms. I quit smoking over 10 years ago, but I’m dealing with the effects of it ...

NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors are ...

Merck’s Winrevair (sotatercept) for PAH Winrevair was greenlit March 26 for treating adults with pulmonary arterial hypertension (PAH), based on ... the excitement is that Ohtuvayre is a ...